Meeting
2019 ASCO Annual Meeting
Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.
Authors
Ibiayi Dagogo-Jack
Massachusetts General Hospital, Boston, MA
Ibiayi Dagogo-Jack , Marguerite Rooney , Rebecca Nagy , Subba Digumarthy , Emily Chin , Jennifer Ackil , Justin F. Gainor , Jessica Jiyeong Lin , Richard B. Lanman , Alice Tsang Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9068)
DOI
10.1200/JCO.2019.37.15_suppl.9068
Abstract #
9068
Poster Bd #
391
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA to investigate resistance mechanism and clone evolution of ALK TKI treated lung adenocarcinoma.
First Author: Gang Hua
Poster
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
First Author: Kaushal Parikh
Poster
2021 ASCO Annual Meeting
Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
First Author: Vineeth Tatineni
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon